Myasthenia gravis: Pathogenesis and treatment

David P Richman, M. A. Agius

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Much is known about the pathogenesis of MG. This information has provided a rational basis for treatment of the disease, which is very effective. On the other hand, present treatments are limited by significant adverse effects. Our knowledge of pathogenesis also provides clues for the development of new, effective, but less toxic treatments. In addition, knowledge of the autoimmune mechanisms in MG may be useful in devising better treatments for the many human autoimmune diseases that are less well understood.

Original languageEnglish (US)
Pages (from-to)106-110
Number of pages5
JournalSeminars in Neurology
Volume14
Issue number2
StatePublished - 1994

Fingerprint

Poisons
Myasthenia Gravis
Autoimmune Diseases

ASJC Scopus subject areas

  • Clinical Neurology
  • Neuroscience(all)

Cite this

Myasthenia gravis : Pathogenesis and treatment. / Richman, David P; Agius, M. A.

In: Seminars in Neurology, Vol. 14, No. 2, 1994, p. 106-110.

Research output: Contribution to journalArticle

Richman, DP & Agius, MA 1994, 'Myasthenia gravis: Pathogenesis and treatment', Seminars in Neurology, vol. 14, no. 2, pp. 106-110.
Richman, David P ; Agius, M. A. / Myasthenia gravis : Pathogenesis and treatment. In: Seminars in Neurology. 1994 ; Vol. 14, No. 2. pp. 106-110.
@article{97d766cbc31348c3959fb13d144a0ee8,
title = "Myasthenia gravis: Pathogenesis and treatment",
abstract = "Much is known about the pathogenesis of MG. This information has provided a rational basis for treatment of the disease, which is very effective. On the other hand, present treatments are limited by significant adverse effects. Our knowledge of pathogenesis also provides clues for the development of new, effective, but less toxic treatments. In addition, knowledge of the autoimmune mechanisms in MG may be useful in devising better treatments for the many human autoimmune diseases that are less well understood.",
author = "Richman, {David P} and Agius, {M. A.}",
year = "1994",
language = "English (US)",
volume = "14",
pages = "106--110",
journal = "Seminars in Neurology",
issn = "0271-8235",
publisher = "Thieme Medical Publishers",
number = "2",

}

TY - JOUR

T1 - Myasthenia gravis

T2 - Pathogenesis and treatment

AU - Richman, David P

AU - Agius, M. A.

PY - 1994

Y1 - 1994

N2 - Much is known about the pathogenesis of MG. This information has provided a rational basis for treatment of the disease, which is very effective. On the other hand, present treatments are limited by significant adverse effects. Our knowledge of pathogenesis also provides clues for the development of new, effective, but less toxic treatments. In addition, knowledge of the autoimmune mechanisms in MG may be useful in devising better treatments for the many human autoimmune diseases that are less well understood.

AB - Much is known about the pathogenesis of MG. This information has provided a rational basis for treatment of the disease, which is very effective. On the other hand, present treatments are limited by significant adverse effects. Our knowledge of pathogenesis also provides clues for the development of new, effective, but less toxic treatments. In addition, knowledge of the autoimmune mechanisms in MG may be useful in devising better treatments for the many human autoimmune diseases that are less well understood.

UR - http://www.scopus.com/inward/record.url?scp=0028108470&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028108470&partnerID=8YFLogxK

M3 - Article

C2 - 7984824

AN - SCOPUS:0028108470

VL - 14

SP - 106

EP - 110

JO - Seminars in Neurology

JF - Seminars in Neurology

SN - 0271-8235

IS - 2

ER -